The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes

Michèle Saïdi, Isabelle Brochériou, Emmanuel Estève, Sophie Tuffet, Zahir Amoura, Makoto Miyara, Xavier Belenfant, Tim Ulinski, Philippe Rouvier, Hanna Debiec, et al.

To cite this version:
Michèle Saïdi, Isabelle Brochériou, Emmanuel Estève, Sophie Tuffet, Zahir Amoura, et al.. The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes. Kidney International Reports, 2021, 6 (7), pp.1977 - 1980. 10.1016/j.ekir.2021.04.025. hal-03335588

HAL Id: hal-03335588
https://hal.sorbonne-universite.fr/hal-03335588
Submitted on 6 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes

Michèle Saïdi1,2, Isabelle Brochériou2,3, Emmanuel Estève2,4, Sophie Tuffet5, Zahir Amoura6, Makoto Miyara6, Xavier Belenfant7, Tim Ulinski8, Philippe Rouvier3, Hanna Debiec2, Pierre Ronco2 and David Buob1,2

1Service d’Anatomie et Cytologie Pathologiques, Hôpital Tenon, Assistance Publique—Hôpitaux de Paris, Sorbonne Université, Paris, France; 2UMRS 1155, Institut National de la Santé et de la Recherche Médicale, Hôpital Tenon, Sorbonne Université, Paris, France; 3Service d’Anatomie et Cytologie Pathologiques, La Pitié Salpêtrière, Assistance Publique—Hôpitaux de Paris, Sorbonne Université, Paris, France; 4Service de Néphrologie et Dialyses, Hôpital Tenon, Assistance Publique—Hôpitaux de Paris, Sorbonne Université, Paris, France; 5Service de Pharmacologie Clinique et Plateforme de Recherche Clinique de l’Est Parisien (URCEST, CRB, CRC), Hôpital Saint-Antoine, Assistance Publique—Hôpitaux de Paris, Sorbonne Université, Paris, France; 6Service de Médecine Interne 2, Maladies Autoimmunes et Systémiques, La Pitié Salpêtrière, Assistance Publique—Hôpitaux de Paris, Sorbonne Université, Paris, France; 7Service de Néphrologie-Dialyse, GHT Grand Paris Nord Est, Hôpital André Grégoire, Montreuil sous Bois, France; and 8Service de Néphrologie Pédiatrique, Hôpital Trousseau, Assistance Publique—Hôpitaux de Paris, Sorbonne Université, Paris, France

Correspondence: David Buob, Service d’Anatomie et Cytologie Pathologiques, Hôpital Tenon, Assistance Publique—Hôpitaux de Paris, Sorbonne Université, 4, rue de la Chine, 75970 Paris Cedex 20, France. E-mail: david.buob@aphp.fr

Received 12 March 2021; revised 16 April 2021; accepted 19 April 2021; published online 5 May 2021

Kidney Int Rep (2021) 6, 1977–1980; https://doi.org/10.1016/j.ekir.2021.04.025

KEYWORDS: exostosin; immunohistochemistry; membranous nephropathy; renal biopsy; systemic lupus erythematosus

© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Exostosin (EXT) 1 and EXT2 proteins are recently discovered major components of the subepithelial deposits in a subset of patients with membranous nephropathy (MN)1,2. Although the detection of EXT1/2 seems to be a distinctive feature of MN related to systemic lupus erythematosus (SLE),1 the exact frequency of EXT-positive, SLE-associated MN (SLE-MN) and its potential clinical significance are not well determined.

Here, we retrospectively evaluated 86 consecutive patients with biopsy-proven pure class 5 SLE-MN diagnosed between January 2010 and December 2018 in 2 nephropathology centers (La Pitié Salpêtrière and Tenon hospitals) in Paris, France; mixed classes (3 + 5 and 4 + 5 of the 2003 ISN/Renal Pathology Society classification)3 were excluded. Immunohistochemistry with anti-EXT1 antibody revealed that 38.4% of the patients (33 of 86) had EXT-positive SLE-MN. The clinical and laboratory features comparing patients with SLE-MN according to the EXT status are described in Table 1. At the time of diagnosis, the EXT-positive patients were younger (33.3 ± 12.9 years vs. 39.9 ± 13.4 years, P = 0.0267), with higher estimated glomerular filtration rate (eGFR) (122.6 ± 52.4 ml/min per 1.73 m² vs. 95.5 ± 48.0, P = 0.0197), and higher amount of urinary protein (3.0 g/d [1.4–4.6] vs. 1.7 [0.9–3.3], P = 0.0334) than EXT-negative patients. Kidney biopsy specimens of EXT-positive patients revealed less glomerular scars (9.1% [3 of 33] with ≥10% sclerosed glomeruli vs. 34.0% [18 of 53] in the EXT-negative group, P = 0.009). MN stages according to the Ehrenreich and Churg classification were evaluated at light microscopy examination and did not differ between the 2 groups. Interestingly, EXT-positive patients were less likely to undergo a repeat biopsy during follow-up and, in such event, had less proliferative lupus nephritis compared with the EXT-negative group (7.7% [2 of 26] vs. 35.7% [15 of 42], P = 0.0189). Data regarding treatment were available in most patients (97.0% [32 of 33] in the EXT-negative group and 94.3% [50 of 53] in the EXT-negative group). In both groups, most patients received hydroxychloroquine (81.3% in the EXT-positive and 82.0% in the EXT-negative patients) and steroids (84.4% in the EXT-positive and 86.0% in the EXT-negative patients). The number of additional
immunosuppressive drugs (mainly mycophenolate mofetil, rituximab, cyclophosphamide, and azathioprine) was not different between the 2 groups ($P = 0.3278$) (Supplementary Table S1). At the end of the follow-up period (50.0 [23.5–75.0] months), EXT-positive patients had better renal function with lower serum creatinine (0.60 [0.55–0.72] mg/dl vs. 0.81 [0.68–0.93] mg/dl, $P = 0.0017$) and higher estimated glomerular filtration rate (114.6 ± 34.5 vs. 84.6 ± 32.3, $P = 0.0006$). Clinical remission, either complete (defined as proteinuria ≤ 0.5 g/d, albuminemia > 30 g/l, and normal serum creatinine) or partial (defined as a decrease in proteinuria by at least 50% with a final value between 0.5 and 3.5 g/d, an increase in albuminemia, and stable serum creatinine), was more frequent in the EXT-positive group (96.3% [26 of 27] vs 68.4% [26 of 38], $P = 0.0056$). In multivariate logistic regression model after adjustment on the follow-up period and MN stage, EXT staining at baseline was associated with complete or partial remission at last follow-up (odds ratio [95% confidence interval] 17.68 [1.78–175.58]) (Table 2). In a very recent publication, Ravindran et al.\textsuperscript{4} reported the clinicopathologic characteristics of a large series of 374 SLE-MN (263 pure class 5 SLE-MN and 111 mixed 3 + 5 and 4 + 5 classes of the 2003 ISN/Renal Pathology Society classification) dichotomized according to the presence or absence of EXT in membranous deposits. Overall, immunohistochemistry revealed that 32.6% (122 of 374) and 35.0% (92 of 263) of the whole cohort and the pure class 5 cases, respectively, were EXT-positive. Kidney biopsy specimens from patients with EXT-positive SLE-MN revealed less chronicity features (glomerulosclerosis, interstitial fibrosis, and tubular atrophy) compared with those from EXT-negative patients. Furthermore, clinical follow-up data, available in 160 patients (129 pure class 5 and 31 mixed 3 + 5/4 + 5 classes), revealed that EXT-negative patients were less likely to reach end-stage kidney disease than EXT-positive patients.

Our results are strikingly similar to those of Ravindran et al.\textsuperscript{4} First, the ratios of EXT-positive among pure class 5 SLE-MN were very similar in Mayo Clinic’s

Table 1. Clinicopathologic characteristics, follow-up, and outcomes of EXT-positive and EXT-negative SLE-MN

| Variables                              | EXT+ n = 33 | EXT- n = 53 | $P$ value |
|----------------------------------------|-------------|-------------|-----------|
| At presentation                        |             |             |           |
| Age, mean ± SD, yr                    | 33.3 ± 12.9 | 39.9 ± 13.4 | 0.0267\textsuperscript{a} |
| Female, n (%)                         | 27 (81.8)   | 45 (84.9)   | 0.7061\textsuperscript{b} |
| SCR, median (IQR), mg/dl              | 0.61 (0.50–0.87), n = 31 | 0.75 (0.60–1.00), n = 49 | 0.0548\textsuperscript{c} |
| eGFR, mean ± SD, ml/min per 1.73 m²    | 122.6 ± 52.4, n = 31 | 96.5 ± 48.0, n = 49 | 0.0197\textsuperscript{d} |
| Proteinuria, median (IQR), g/24 h      | 3.0 (1.4–4.6), n = 32 | 1.7 (0.9–3.3), n = 49 | 0.0334\textsuperscript{e} |
| Proteinuria > 3.0 g/24 h, n (%)       | 16 (50.0), n = 32 | 15 (30.6), n = 49 | 0.0793\textsuperscript{f} |
| Hematuria, n (%)                      | 8 (40.0), n = 20 | 18 (51.4), n = 35 | 0.4141\textsuperscript{g} |
| Sclerosed glomeruli                   |             |             |           |
| <10%                                   | 30 (90.9)   | 35 (66.0)   |           |
| ≥10%                                   | 3 (9.1)     | 18 (34.0)   |           |
| Interstitial fibrosis                  |             |             | 0.0803\textsuperscript{h} |
| Grade 0                                | 28 (84.8)   | 36 (67.9)   |           |
| Grade ≥1                               | 5 (15.2)    | 17 (32.1)   |           |
| Follow-up                              |             |             |           |
| Repeat biopsy                          | n = 26      | n = 42      | 0.0189\textsuperscript{i} |
| Class 3 or 4                           | 2 (7.7)     | 15 (35.7)   |           |
| Other                                  | 3 (11.5)    | 2 (4.8)     |           |
| No renal biopsy                        | 21 (60.8)   | 25 (59.5)   |           |
| At end of follow-up                    |             |             |           |
| SCR, median (IQR), mg/dl              | 0.60 (0.55–0.72), n = 27 | 0.81 (0.68–0.93), n = 38 | 0.0017\textsuperscript{j} |
| eGFR, mean ± SD, ml/min per 1.73 m²    | 114.6 ± 34.5, n = 27 | 84.6 ± 32.3, n = 38 | 0.0006\textsuperscript{k} |
| Proteinuria, median (IQR), g/24 h      | 0.30 (0.11–0.60), n = 27 | 0.39 (0.20–1.36), n = 38 | 0.2413\textsuperscript{l} |
| Proteinuria > 3.0 g/24 h, n (%)       | 2 (7.4), n = 27 | 3 (7.9), n = 38 | 1.0000\textsuperscript{m} |
| Clinical remission                     | n = 27      | n = 38      | 0.0066\textsuperscript{n} |
| Complete                               | 19 (70.4)   | 21 (55.3)   |           |
| Partial                                | 7 (25.9)    | 5 (13.2)    |           |
| No remission                           | 1 (3.7)     | 12 (31.6)   |           |
| Time of follow-up, median (IQR), mo    | 39.0 (22.0–79.0), n = 27 | 57.0 (27.0–75.0), n = 41 | 0.4620\textsuperscript{o} |

eGFR: estimated glomerular filtration rate; EXT: exostosin; IQR: interquartile range; SCR: serum creatinine; SLE-MN, systemic lupus erythematosus-associated membranous nephropathy.

\textsuperscript{a}Student’s $t$ test.
\textsuperscript{b}Pearson’s chi-square test.
\textsuperscript{c}Wilcoxon rank sum test.
\textsuperscript{d}Fisher’s exact test.

Interstitial fibrosis grading is based on Banff classification.
cohort and the current study, being 35.0% and 38.4%, respectively. Second, both studies remarkably revealed that, at baseline, EXT-positive patients were younger, with better renal function, greater daily proteinuria, and less renal parenchyma scars on biopsy specimens. Third, after a similar follow-up period, both studies found that renal prognosis was better in the EXT-positive cases, in terms of both renal function and proteinuria. Thus, our series can be considered as an independent validation cohort of the study by Ravindran et al.4

Our work brings additional original findings. First, owing to a closer histologic follow-up in our series (patients are mostly sedentary), we found that EXT-negative patients had significantly more repeat biopsies with proliferative class 3 or 4 lupus nephritis since the diagnosis of SLE-MN. The possibility for patients with SLE-MN to evolve toward proliferative glomerulonephritis is a well-known pejorative and relatively frequent event challenging the management of patients with lupus.5,6 Although other studies are needed to confirm this result, EXT immunohistochemical typing may help in stratifying patients with SLE-MN according to their risk of evolution toward proliferative lupus nephritis and therefore dictate personalized clinical monitoring. The presence of EXT in the immune deposits seems to be associated with a better prognosis also in the patients with mixed (3 + 5 and 4 + 5) classes as they did not develop end-stage kidney disease despite proliferative lesions as compared with those that were EXT negative in the Mayo Clinic study.5 Second, multivariable analysis suggested that the EXT status independently predicted clinical remission at the end of follow-up. Nevertheless, this analysis should be considered as exploratory given the relatively small number of patients and the large confidence intervals of odds ratio, and the results should be confirmed by studies focusing on time to clinical response postbiopsy.

The mechanisms leading to the subepithelial accumulation of EXT1/2 and its pathophysiological consequences remain to be elucidated. It is not known whether EXT1/2 is an antigen or a biomarker as antibodies have not been identified yet. The heterodimer formed by EXT1 and EXT2 seems to play a key role in the making of the glomerular basement membrane by adding glycosyl residues to the protein core of proteoglycans.7 One may hypothesize that diversion of this enzyme to immune deposits might alter the glomerular basement membrane biosynthesis and account for the higher proteinuria at the time of kidney biopsy, but the discrepancy between the better prognosis of EXT-positive SLE-MN and the higher proteinuria at baseline remains intriguing and unexplained.

In summary, our findings echo to those of the Mayo Clinic5 and suggest that patients with EXT-positive SLE-MN have better renal outcome compared with patients with EXT-negative SLE-MN despite greater proteinuria at diagnosis. In light of these results, we recommend that immunohistochemical phenotyping of SLE-MN with anti-EXT antibody should be systematically performed by pathologists. Further studies are

---

**Table 2. Multivariable logistic regression model of the risk of remission at last follow-up (n = 47 of 60)**

| Variables                          | OR (95% CI)                  | P value of type III test | OR (95% CI)                  | P value of type III test |
|------------------------------------|------------------------------|--------------------------|------------------------------|--------------------------|
| Follow-up period (mo)              | 1.01 (0.99–1.03)             | 0.4609                   | 1.01 (0.98–1.03)             | 0.6110                   |
| MN stages                          |                              |                          |                              |                          |
| I                                  | 1                            |                          | 1                            |                          |
| II                                 | 0.52 (0.09–2.91)             | 0.72 (0.11–4.62)         |                              |                          |
| III–IV                             | 0.15 (0.02–0.99)             | 0.12 (0.01–1.18)         |                              |                          |
| EXT status                         |                              |                          |                              |                          |
| Negative                           | 1                            |                          | 0.0194                       | 0.0142                   |
| Positive                           |                              |                          | 12.52 (1.50–104.12)         | 17.68 (1.78–175.58)      |
| eGFR <90 ml/min per 1.73 m²        |                              |                          |                              |                          |
| No                                 |                              |                          | 0.1581                       |                          |
| Yes                                | 0.40 (0.11–1.43)             |                          |                              |                          |
| Interstitial fibrosis = 0          |                              |                          | 0.0433                       |                          |
| No                                 |                              |                          | 4.27 (1.04–17.46)           |                          |
| Yes                                |                              |                          | 0.1416                       |                          |
| ≥2 Immunosuppressive drugs (except hydroxychloroquine and steroids) |                              |                          |                              |                          |
| No                                 |                              |                          | 0.39 (0.11–1.37)            |                          |
| Yes                                |                              |                          |                              |                          |

CI, confidence interval; eGFR, estimated glomerular filtration rate; EXT, exostosin; MN, membranous nephropathy; OR, odds ratio.

Variable forced in the multivariable model.
needed to determine whether therapeutic approach should be different according to the EXT status of patients with SLE-MN.

DISCLOSURE
All the authors declared no competing interests.

ACKNOWLEDGMENTS
MS received a research grant from the Francophone Society of Nephrology, Dialysis, and Transplantation. The authors acknowledge the contribution of S. Ouchelouche (UMRS 1155, Institut National de la Santé et de la Recherche Médicale, Tenon Hospital, Paris, France) and the technical staff of the Pathology Department of Tenon Hospital.

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Methods.
Table S1: Treatment of SLE-MN.

REFERENCES
1. Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol. 2019;30:1123–1136.
2. Hanset N, Aydin S, Demoulin N, et al. Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study. Am J Kidney Dis. 2020;76:624–635.
3. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–530.
4. Ravindran A, Casal Moura M, Fervenza FC, et al. In patients with membranous nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes. J Am Soc Nephrol. 2021;32:695–706.
5. Mercadal L, Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant. 2002;17:1771–1778.
6. Sun HO, Hu WX, Xie HL, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus. 2008;17:56–61.
7. Bosse-Wicher M, Wicher KB, Kusche-Guliberg M. The exostosin family: proteins with many functions. Matrix Biol. 2014;35:25–33.